Codagenix Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25M

  • Investors
  • 11

Codagenix General Information

Description

Developer of live-attenuated viral vaccine design technology designed to provide target antigens placed in an attenuated backbone virus. The company's vaccines use synthetic attenuated virus engineering, which is based on synthetic biology and is re-designed for the entire genome to yield a vaccine strain, enabling the healthcare industry with viral vaccines to treat influenza, dengue, polio, and other diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3 Bioscience Park Drive
  • Farmingdale
  • New York, NY 11735
  • United States
+1 (631)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3 Bioscience Park Drive
  • Farmingdale
  • New York, NY 11735
  • United States
+1 (631)

Codagenix Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Codagenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Later Stage VC (Series B) 10-Feb-2023 $25M Completed Clinical Trials - Phase 3
17. Later Stage VC (Series B) 28-Jun-2022 Completed Clinical Trials - Phase 3
16. Later Stage VC (Series B) 14-Oct-2021 Completed Clinical Trials - Phase 3
15. Grant 06-May-2021 Completed Clinical Trials - Phase 3
14. Later Stage VC (Series B) 18-Mar-2021 Completed Clinical Trials - Phase 3
13. Grant 22-Jul-2020 Completed Clinical Trials - Phase 3
12. Later Stage VC (Series B) 10-Jan-2020 Completed Clinical Trials - Phase 3
11. Grant 31-Dec-2017 Completed Clinical Trials - Phase 3
10. Later Stage VC 12-Oct-2017 $1.4M $5.5M Completed Clinical Trials - Phase 3
9. Grant 16-Aug-2017 $809K $4.1M Completed Clinical Trials - Phase 3
To view Codagenix’s complete valuation and funding history, request access »

Codagenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A5
Series A4
Series A3
Series A2 3,619,189 $0.000010 6% $0.55 $0.55 1x $0.55 12.47%
Series A1 187,266 $0.000010 6% $0.27 $0.27 1x $0.27 0.65%
To view Codagenix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Codagenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of live-attenuated viral vaccine design technology designed to provide target antigens placed in an attenuated
Drug Discovery
New York, NY
27 As of 2024

Rochester, MN
 

Needham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Codagenix Competitors (3)

One of Codagenix’s 3 competitors is Vyriad, a Venture Capital-Backed company based in Rochester, MN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vyriad Venture Capital-Backed Rochester, MN
Candel Therapeutics Formerly VC-backed Needham, MA
Dynavax Technologies Formerly VC-backed Emeryville, CA
You’re viewing 3 of 3 competitors. Get the full list »

Codagenix Patents

Codagenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250025547-A1 Parenterally administrable influenza vaccine and uses thereof Pending 02-Dec-2021
AU-2022306850-A1 Deoptimized sars-cov-2 variants and methods and uses thereof Pending 07-Jul-2021
AU-2022307684-A1 Deoptimized yellow fever virus and methods and uses thereof Pending 07-Jul-2021
CA-3229050-A1 Deoptimized sars-cov-2 variants and methods and uses thereof Pending 07-Jul-2021
CA-3223214-A1 Deoptimized yellow fever virus and methods and uses thereof Pending 07-Jul-2021 A61K39/12
To view Codagenix’s complete patent history, request access »

Codagenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Codagenix Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adjuvant Capital Impact Investing Minority
Euclidean Capital Family Office Minority
In-Q-Tel Not-For-Profit Venture Capital Minority
Serum Institute of India PE-Backed Company Minority
Topspin Consumer Partners PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Codagenix FAQs

  • When was Codagenix founded?

    Codagenix was founded in 2011.

  • Where is Codagenix headquartered?

    Codagenix is headquartered in New York, NY.

  • What is the size of Codagenix?

    Codagenix has 27 total employees.

  • What industry is Codagenix in?

    Codagenix’s primary industry is Drug Discovery.

  • Is Codagenix a private or public company?

    Codagenix is a Private company.

  • What is Codagenix’s current revenue?

    The current revenue for Codagenix is .

  • How much funding has Codagenix raised over time?

    Codagenix has raised $56M.

  • Who are Codagenix’s investors?

    Adjuvant Capital, Euclidean Capital, In-Q-Tel, Serum Institute of India, and Topspin Consumer Partners are 5 of 11 investors who have invested in Codagenix.

  • Who are Codagenix’s competitors?

    Vyriad, Candel Therapeutics, and Dynavax Technologies are competitors of Codagenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »